VEGF inhibitors, such as the anti-VEGF antibody bevacizumab, were shown to be effective in treating hepatic vascular malformations in addition to nose and gastrointestinal bleeding in HHT patients [28,29,30,31,32,33,34]. The gene discussed is VEGFA; the disease is hereditary hemorrhagic telangiectasia.